A Phase 2 interventional study of Alpha1-Proteinase Inhibitor (Human) and Albumin (Human) 20%, United States Pharmacopeia (USP) in Alpha 1-Antitrypsin Deficiency, sponsored by Grifols Therapeutics LLC. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-21.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency — 2 open to participants now, 2 under way, 1 of them phase 3. alpha 1-Antitrypsin · alpha 1-Antitrypsin Deficiency.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, this one is the 6th largest by enrollment, is the only one that started in 2003, is one of 6 in phase 2, and was the 1st registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →2 of the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency are open now, in 12 countries. Recruiting first, the newest first:
CSL Behring · Sites in Denmark
Ages 18–65
Grifols Therapeutics LLC · Sites in United States, Australia, Canada and 9 more countries
Ages 20–72
By country, each count listing its studies:
alpha 1-Antitrypsin: first FDA approval 1987 (prolastin,prolastin-c,prolastin-c liquid), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 7 · Phase 4 6
First in 2003; this study’s year is marked. 1 started in 2003.
This study's enrollment of 77 is above the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 30 across the 25 interventional studies. Of the 19 that completed or were terminated, 16 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
12 studies in alpha 1-Antitrypsin Deficiency by Grifols: 2 open now, 2 under way, 2 of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 12 studies in alpha 1-Antitrypsin Deficiency by Grifols, this one is the 3rd largest by enrollment, is the only one that started in 2003, is one of 4 in phase 2, and was the 1st registered.
Grifols’s alpha 1-Antitrypsin Deficiency studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing alpha 1-Antitrypsin in alpha 1-Antitrypsin Deficiency, from their registry updates:
Among Grifols’s 12 in alpha 1-Antitrypsin Deficiency:
This tab as a report to print or save as PDF → With an account.
The goal of this trial was to explore the utility of evaluating emphysema progression through CT scans measuring lung density during a 2 year period of weekly infusions of either placebo or human alpha-1-antitrypsin (AAT; Prolastin®). Exacerbation data recorded in patient diaries were also collected. All efficacy data were analyzed for potential use in evaluating Prolastin efficacy in this and other clinical trials.
This is a one to one randomized, placebo-controlled, clinical, exploratory study with the aim of collecting information on possible clinical endpoints i.e., the progression of emphysema by lung density measurements with CT scan and frequency of exacerbations that could be used for a subsequent placebo controlled clinical trial. Progression of disease will be investigated in 80 patients with alpha-1-antitrypsin deficiency, who will be treated with human alpha-1-antitrypsin (AAT; Prolastin®) or placebo weekly for two years to analyze the effect of treatment on lung density and exacerbations. Targeted augmentation therapy with weekly infusions of Prolastin® will be a dose of 60 mg/kg body weight (range of 51.72 to 71.43 mg per kg body weight).
Therefore, this study focuses on several questions:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prolastin
Drug: Alpha1-Proteinase Inhibitor (Human)
Drug: Albumin (Human) 20%, United States Pharmacopeia (USP)
Weekly infusion of 60 mg/kg body weight for 2 years
Also known as: Prolastin, alpha-1 antitrypsin (AAT), BAY x 5747, BAY 10-5233, TAL-05-00007, NDC 13533-601-30, NDC 13533-601-35
Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
Also known as: Plasbumin®-20, Plasbumin®-20 (Low Aluminum), Albumin (Human) 20%, TAL-05-00008, TAL-05-00024, BAY 34-9255, NDC 3533-683-20, NDC 1533-683-71, NDC 13533-691-20, NDC 13533-691-71
The Progression Rate of Emphysema Determined by Change in 15th Percentile of Lung Density Measured by Annual CT Scan of the Whole Lung
Time frame: 24 or 30 months
Change in Lung Density at Each Visit as Measured by Computed Tomography
Time frame: 24 or 30 months
The Frequency of Exacerbations as Determined by Patient Diary.
Time frame: 24 or 30 months
The Deterioration of the Lung Function Will be Assessed by Measurement of the Change in Forced Expiratory Volume at One Second (FEV1) and Transfer Factor of Carbon Monoxide (KCO)
Time frame: 24 or 30 months
Duration and Severity of the Exacerbations
Time frame: 24 or 30 months
Mortality
Time frame: 24 or 30 months
Quality of Life With a Disease Specific Instrument, the St. George's Respiratory Questionnaire
Time frame: 24 or 30 months
Multicenter study with 3 sites in Denmark, Sweden, and the United Kingdom.
| Milestone | Prolastin (60 mg/kg Body Weight) | Placebo |
|---|---|---|
| Started | 38 | 39 |
| Completed | 35 | 32 |
| Not completed | 3 | 7 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Lung transplantation | 1 | 2 |
| Withdrew: Too ill to attend visit | 1 | 0 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Disease progression | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| g/L | Prolastin (60 mg/kg Body Weight) | Placebo |
|---|---|---|
| Baseline | 47.980 ± 19.072 | 45.477 ± 16.949 |
| Endpoint | 45.085 ± 19.433 | 41.354 ± 16.260 |
| Change from Baseline | -2.895 ± 4.739 | -4.124 ± 4.147 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prolastin (60 mg/kg Body Weight) | — | 9/38 (23.7%) | 37/38 (97.4%) |
| Placebo | — | 15/39 (38.5%) | 38/39 (97.4%) |
| Event | Prolastin (60 mg/kg Body Weight) | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 3/38 | 4/39 |
| Atrial fibrillationCardiac disorders | 2/38 | 0/39 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/38 | 0/39 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/38 | 2/39 |
| ConstipationGastrointestinal disorders | 1/38 | 0/39 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/38 | 0/39 |
| Biliary colicHepatobiliary disorders | 1/38 | 0/39 |
| Gallbladder disorderHepatobiliary disorders | 1/38 | 1/39 |
| MalariaInfections and infestations | 1/38 | 0/39 |
| Upper limb fractureInjury, poisoning and procedural complications | 1/38 | 0/39 |
| Event | Prolastin (60 mg/kg Body Weight) | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 24/38 | 22/39 |
| PneumoniaInfections and infestations | 12/38 | 9/39 |
| HeadacheNervous system disorders | 9/38 | 10/39 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 8/38 | 3/39 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/38 | 6/39 |
| SinusitisInfections and infestations | 5/38 | 5/39 |
| Back painMusculoskeletal and connective tissue disorders | 5/38 | 2/39 |
| DiarrhoeaGastrointestinal disorders | 3/38 | 5/39 |
| Chest painGeneral disorders | 2/38 | 5/39 |
| Oedema peripheralGeneral disorders | 1/38 | 5/39 |
| Age, Categorical(Participants) | Prolastin (60 mg/kg Body Weight) | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 33 | 34 | 67 |
| >=65 years | 5 | 5 | 10 |
| Age, Continuous(years) | Prolastin (60 mg/kg Body Weight) | Placebo | Total |
|---|---|---|---|
| Mean | 54.68 ± 8.29 | 55.26 ± 9.68 | 54.97 ± 9.03 |
| Sex: Female, Male(Participants) | Prolastin (60 mg/kg Body Weight) | Placebo | Total |
|---|---|---|---|
| Female | 13 | 23 | 36 |
| Male | 25 | 16 | 41 |
| Region of Enrollment(participants) | Prolastin (60 mg/kg Body Weight) | Placebo | Total |
|---|---|---|---|
| Denmark | 18 | 17 | 35 |
| United Kingdom | 12 | 14 | 26 |
| Sweden | 8 | 8 | 16 |
| Severity of COPD at baseline(participants) | Prolastin (60 mg/kg Body Weight) | Placebo | Total |
|---|---|---|---|
| None | 2 | 2 | 4 |
| Mild | 1 | 2 | 3 |
| Moderate | 10 | 8 | 18 |
| Severe | 19 | 20 | 39 |
| Very Severe | 6 | 7 | 13 |
The record gives a start of Dec 2003, a primary completion of Jan 2007 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 7 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin
alpha 1-Antitrypsin Deficiency →